QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
NASDAQ:RNA

Avidity Biosciences - RNA Competitors

$15.35
-1.45 (-8.63%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.07
$16.21
50-Day Range
$16.80
$25.65
52-Week Range
$9.83
$25.74
Volume
3.50 million shs
Average Volume
988,644 shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60

RNA vs. TVTX, DICE, SNDX, MORF, ARVN, CVAC, VRNA, RCKT, KDNY, and RCUS

Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Travere Therapeutics (TVTX), DICE Therapeutics (DICE), Syndax Pharmaceuticals (SNDX), Morphic (MORF), Arvinas (ARVN), CureVac (CVAC), Verona Pharma (VRNA), Rocket Pharmaceuticals (RCKT), Chinook Therapeutics (KDNY), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.

Avidity Biosciences vs.

Travere Therapeutics (NASDAQ:TVTX) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

In the previous week, Avidity Biosciences had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Avidity Biosciences and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.11 beat Avidity Biosciences' score of 0.11 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avidity Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Travere Therapeutics has a net margin of -131.35% compared to Avidity Biosciences' net margin of -1,886.33%. Avidity Biosciences' return on equity of -40.82% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics -131.35% -219.11% -37.05%
Avidity Biosciences -1,886.33% -40.82% -36.41%

Avidity Biosciences has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$212.02 million6.87-$278.48 million-$4.37-5.15
Avidity Biosciences$9.22 million117.89-$173.99 million-$3.33-4.61

Travere Therapeutics currently has a consensus price target of $32.91, indicating a potential upside of 46.33%. Avidity Biosciences has a consensus price target of $43.60, indicating a potential upside of 184.04%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Avidity Biosciences
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Avidity Biosciences received 90 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 63.45% of users gave Avidity Biosciences an outperform vote while only 49.30% of users gave Travere Therapeutics an outperform vote.

CompanyUnderperformOutperform
Travere TherapeuticsOutperform Votes
35
49.30%
Underperform Votes
36
50.70%
Avidity BiosciencesOutperform Votes
125
63.45%
Underperform Votes
72
36.55%

Summary

Avidity Biosciences beats Travere Therapeutics on 12 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNA vs. The Competition

MetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.09B$5.65B$4.41B$6.02B
Dividend YieldN/A2.59%2.42%6.33%
P/E Ratio-4.615.0594.4212.90
Price / Sales117.89284.783,572.1956.27
Price / CashN/A17.9228.2665.84
Price / Book1.854.294.585.09
Net Income-$173.99M$187.05M$114.80M$191.80M
7 Day Performance-23.36%2.77%2.17%2.58%
1 Month Performance-35.23%-6.51%-5.48%-4.25%
1 Year Performance-16.89%-9.68%-14.15%-15.97%

Avidity Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVTX
Travere Therapeutics
2.2239 of 5 stars
$22.89
+5.7%
$32.91
+43.8%
-12.0%$1.40B$212.02M-5.24310Positive News
DICE
DICE Therapeutics
1.9636 of 5 stars
$29.36
-0.5%
$65.86
+124.3%
+48.5%$1.40B$1.13M-13.7246Analyst Report
Insider Buying
Short Interest ↑
News Coverage
Gap Up
SNDX
Syndax Pharmaceuticals
2.4096 of 5 stars
$21.55
+1.1%
$33.57
+55.8%
+19.8%$1.47B$139.71M-8.8059
MORF
Morphic
2.3623 of 5 stars
$37.89
+1.3%
$65.71
+73.4%
-7.6%$1.48B$70.81M-23.83101
ARVN
Arvinas
1.987 of 5 stars
$27.87
+6.6%
$68.75
+146.7%
-58.0%$1.48B$131.40M-5.24280
CVAC
CureVac
2.1951 of 5 stars
$6.70
+4.4%
$24.33
+263.2%
-65.4%$1.49B$115.57M0.00455
VRNA
Verona Pharma
1.9772 of 5 stars
$20.18
+0.6%
$29.33
+45.4%
+275.3%$1.53B$460,000.00-18.0224News Coverage
Positive News
RCKT
Rocket Pharmaceuticals
2.6937 of 5 stars
$16.75
+6.1%
$52.58
+213.9%
+2.1%$1.33BN/A-5.09151
KDNY
Chinook Therapeutics
2.1149 of 5 stars
$23.42
+3.0%
$38.00
+62.3%
+40.7%$1.54B$6.13M-8.13138Short Interest ↑
Positive News
RCUS
Arcus Biosciences
2.2897 of 5 stars
$18.05
+2.4%
$41.33
+129.0%
-47.7%$1.32B$112M-4.85366
This page (NASDAQ:RNA) was last updated on 3/31/2023 by MarketBeat.com Staff